Back to the Top
Something which puzzles me as I read through the regulatory guidelines for BCS-based biowaivers: why does the FDA require the BCS classification of a drug substance to be redone for a BCS-based biowaiver when this would have been done for the innovator drug substance anyway? I note that the EMA seems to be of the opposite opinion. As far as the formulations are similar, I would not expect the classification to be any different between the innovator and the generic, so is this not a duplication of work?
Perhaps I have missed some crucial link in the thinking behind this, so I would be happy to hear any educated opinions.
Thanks and regards,
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Re-determine BCS class for a BE biowaiver" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)